Scholarlink

Background <p>Tenofovir is a primary treatment for chronic hepatitis B (CHB) infections. While hepatic fibrosis regression during antiviral therapy has been documented, data on the effects of prolonged tenofovir disoproxil fumarate (TDF) treatment on Fibroscan results is limited. This case series will significantly contribute to the understanding of fibrosis improvement in CHB patients undergoing long-term TDF therapy.</p> Case presentation <p>We present four patients with CHB patients receiving long-term TDF therapy. Fibrosis levels were assessed using Fibroscan before and after treatment to evaluate changes in hepatic fibrosis.</p> Discussion <p>Overall, these cases underscore that timely initiation of antiviral therapy, coupled with regular monitoring, can lead to significant improvements in liver function and fibrosis in CHB patients. The findings support the notion that effective antiviral treatments can reverse the course of liver disease, reduce complication risks, and enhance overall patient well-being.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tenofovir and fibrosis improvement in chronic hepatitis B: insights from a case series

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月24日

查看全文
  • Hamid Ghorbani,
  • Saina Adib Amin,
  • Reza Jafarzadeh Esfehani,
  • Mohammad Reza Hadizadeh,
  • Raheleh Miri,
  • Sanaz Ahmadi Ghezeldasht

摘要

Background

Tenofovir is a primary treatment for chronic hepatitis B (CHB) infections. While hepatic fibrosis regression during antiviral therapy has been documented, data on the effects of prolonged tenofovir disoproxil fumarate (TDF) treatment on Fibroscan results is limited. This case series will significantly contribute to the understanding of fibrosis improvement in CHB patients undergoing long-term TDF therapy.

Case presentation

We present four patients with CHB patients receiving long-term TDF therapy. Fibrosis levels were assessed using Fibroscan before and after treatment to evaluate changes in hepatic fibrosis.

Discussion

Overall, these cases underscore that timely initiation of antiviral therapy, coupled with regular monitoring, can lead to significant improvements in liver function and fibrosis in CHB patients. The findings support the notion that effective antiviral treatments can reverse the course of liver disease, reduce complication risks, and enhance overall patient well-being.